Akari Therapeutics
$1.639876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.05 (-2.98%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell AKTX and other stocks, options, and ETFs commission-free!
About AKTX
Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom. The listed name for AKTX is Akari Therapeutics Plc ADR.
Employees
10
Headquarters
London, London & South East
Founded
2004
Market Cap
55.20M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
227.26K
High Today
$1.74
Low Today
$1.64
Open Price
$1.71
Volume
149.99K
52 Week High
$2.79
52 Week Low
$0.87
Collections
AKTX Earnings
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 2, Pre-Market